Drug intelligence / Profile preview

THP-006A

Development stage: Unknown
Lead developer: THPharm
Administration: Oral

Overview

**THP-006A** is a THPharm pipeline drug candidate. THPharm’s public pipeline homepage identifies THP-006A by this development code, but currently provides no drug-specific disclosure of its active ingredient, molecular target, modality, mechanism of action, formulation, route of administration, indication, or clinical development phase. THPharm focuses broadly on incrementally modified and repurposed therapies for metabolic diseases, but a specific disease assignment for THP-006A cannot be confirmed from the available public information. ([thpharm.kr](https://thpharm.kr/))

Targets

NEP (Neutral Endopeptidase)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on THP-006A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THP-006A.

Explore the full profile